Cathy Eng, Professor of Medicine and David H. Johnson Chair in Surgical and Medical Oncology at Vanderbilt-Ingram Cancer Center, shared on X:
“Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China ”
You can also read:ctDNA Identifies High Recurrence Risk After Resection of Stage I–III Biliary Tract Cancer
